Indication intelligence, analysis and sector perception

RegMed’s close: wait and watch 2016, it could be a year of living dangerously

January 4, 2016 5:29pm

Volatility points to increased risk although historical data has found the first trading day of the year had little predictive value on the full year's return

However, “our” universe is oversold and a set-up for selective appreciation

Subscribe for access or take your losses without complaining …

I say what others won't, so you can do what others can't!

Stocks greeted 2016 by sliding more than 1% Monday, hurt by a rout in Chinese stocks overnight and increased tensions in the Middle East. The NASDAQ slumped 2.1%, the Dow lost 1.6% and the S&P 500 fell 1.5%.

All three indexes were off more than 2% most of the day. Volume jumped 69% on the NYSE and 61% on the NASDAQ compared to Thursday's pre-holiday levels, according to preliminary data.

The NASDAQ closed DOWN -104.32 or -2.08% to 4,903.09 and the DOW closed DOWN -274.28 or -1.57% to 17,150.75.

Henry’omics:

The stem, cell and gene therapy RegMed (SCGT&RM) sector opened negative, continued negative at the mid-day to close negative (of 43 covered companies);

My fear gauge or the CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded near 22 after earlier topping 23 to hit its highest level in two weeks following Thursday’s near 18 following Wednesday‘s near 17 after Tuesday’s 16 from last Monday’s 17.

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The stem, cell and gene therapy RegMed sector opened negative with an A/DL of 7/32 and 4 flats leading up to a negative mid-day with an A/DL of 5/38 and 0 flats closing negative in Monday’s session with an A/DL of 7/33 and 3 flats.

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed DOWN Monday -11.46 or -3.39% following Thursday’s decline of -2.53 or -0.74% after Wednesday’s -2.25 or -0.66% after Tuesday’s advance of +5.89 or +1.75% following last Monday’s decline of -2.57 or -0.76%;

The NASDAQ Biotechnology index (NBI) closed DOWN on Monday -112.78 or -3.19% following Thursday’s decline of -25.49 or -0.71 after Wednesday’s decline of -24.16 or -0.67% after Tuesday’s +64.13 or +1.82% following last Monday’s decline of -29.09 or -0.82%;

The Russell 2000 (IWM) closed DOWN on Monday -2.61 or -2.32% following Thursday’s decline of -1.42 or -1.25% after Wednesday’s -1.16 or -1.01% after Tuesday’s advance of +1.27 or +1.11% following last Monday’s decline of -0.53 or -0.46%;

The SPDR SD&P Biotech ETF (XBI) closed DOWN on Monday -2.41 or -3.43% following Thursday’s decline of - 0.66 or -0.93% after Wednesday’s decline of -0.79 or -1.10% after Tuesday’s +1.82 or +2.61% following last Monday’s decline of -1.16 or -1.64% …

Dosing the sector – what a day for the 43 Patients:

Open: NEGATIVE with 32 decliners, 7 advancers and 4 flats;

Mid-day (12:30 pm): NEGATIVE with 38 decliners, 5 advancers and 0 flats;

Closing bell: NEGATIVE with 33 decliners, 7 advancers and 3 flats

Who was UP – top 5:

Regenxbio (RGNX) closed up +$0.40 to $17.00;
Kite Pharma (KITE) +$0.30 to $61.92;
ReNeuron (RENE.L) +$0.25 to $3.25;
Brainstorm (BCLI) +$0.09 to $2.95
VistaGen (VSTA) closed UP +$0.06 to $9.90;

Who closed down – top 5:

Spark Therapeutics (ONCE) closed down -$3.46 to $41.85;
Aduro Biotech (ADRO) -$1.40 to $26.74;
Bellicum (BLCM) -$1.27 to $19.00;
Intrexon (XON) -$0.98 to $29.17;
Cellectis (CLLS) closed down -$0.87 to $30.16

Flat:

Caladrius Bioscience (formerly NeoStem (NBS) at $1.08;
Neuralstem (CUR) at $%1.03;
Pluristem (PSTI) at $1.13;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.